Abstract: Provided are compositions, devices and methods for deterring coprophagy in canines.

Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

Abstract: Methods and compositions involving exosomes or lipid nanovesicles are provided. For example, certain aspects relate to compositions comprising exosomes obtained from cells that have been induced to undergo oxidative stress or stimulated. Furthermore, some aspects of the invention provide methods of treating a subject at risk or having a demyelinating disorder using the compositions.

Abstract: The present invention provides chimeric antigen receptors, cells expressing same and methods of using same for treatment various disorders such as cancer, autoimmune disorders and graft vs host disease.

Abstract: Disclosed are a pharmaceutical composition comprising a PD-1 antibody and non-specifically amplified and activated T cells, and the use thereof. The pharmaceutical composition of the present invention comprises the PD-1 antibody and non-specifically amplified and activated T cells. The two components have a synergistic effect, can inhibit the growth of renal cancer cells and have a killing effect on renal cancer cells.

Abstract: Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway and cells, such as immune cells, prepared in vitro with the compounds. The compounds and cells can be used to treat a number of conditions, including infectious diseases, hyperproliferative disorders, inborn errors of metabolism, chronic immunometabolic diseases, autoimmune diseases, organ transplant rejection, inflammatory disorders, and chronic pain, among others.

Abstract: Non-coding RNA, such as miRNA, expression data derived from a cell population is used to infer the propensity of that cell population for a cellular functional effect for a pre-determined purpose, which effect is temporally, procedurally or interventionally separated from the cell population from which the expression data is derived. Thereby, the cellular functional effect of a cell population can be predicted in order to improve decisions and selections to be made relating to the use of cells, e.g. from cells deriving from different donors or batches, for use in bioprocess application or cell therapeutics, in order to enhance productivity, efficiency and/or efficacy.

Abstract: The disclosure provides, e.g., enucleated erythroid cells comprising an amino acid degradative enzyme such as asparaginase and a targeting moiety such as an anti-CD33 antibody molecule. The cells may be used, e.g., to treat cancers such as AML.

Abstract: The present invention relates to platelet-rich plasma (PRP) for epicutaneous use in a wide range of applications in the cosmetic and dermatological fields and to a functional bioactive composition suitable for topical use, which comprises said PRP and allows complete absorption into the skin, hair or scalp, and which has a regenerating action for relaxing expression wrinkles, a lifting effect for sustaining relaxed skin tissues, for scar reduction and wound healing. The present composition performs a regenerating and a repairing action on the skin cell layers, combining the benefits of increasing vitality and longevity of the skin, scalp and hair follicle, without the disadvantages of invasive techniques. The present composition is formulated to allow complete absorption of the PRP and guarantees the vital function of platelet growth factors while combining a gradual, more physiological releasing rate, and stimulating the recruiting of stem cells.

Abstract: The invention concerns a pharmaceutical composition comprising a platelet lysate and its use to treat a wound, an anal fissure, vaginal atrophy or a wrinkle.

Abstract: The present disclosure relates to a method for selecting a high efficacy stem cell for treating intraventricular hemorrhage in premature infants, and more particularly, to a method for selecting a high efficacy stem cell for treating intraventricular hemorrhage, including a step of measuring an expression level of a vascular endothelial growth factor (VEGF) and a high efficacy stem cell selected by the method.

Abstract: This invention is directed to compositions and methods for treating a condition of the heart. In an embodiment, the invention is directed to a method of treating a subject in need thereof, wherein the method comprises ablating at least one nerve of the renal artery of the subject; and administering to the subject a therapeutically effective amount of cells.

Abstract: A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.

Abstract: A bone marrow fluid of a patient is sampled, housed in a collection tube 11 and conveyed into an isolator in a sterile state. In the isolator, the bone marrow fluid in the collection tube is pipetted into test tubes and culture tube, etc. To the bone marrow fluid in the tubes, an erythrocyte sedimentation agent is added. After precipitating erythrocytes, the supernatant is collected. From the collected supernatant, a bone marrow cell-containing fraction for liver regeneration is concentrated and pipetted into flasks which are conveyed into an incubator to start the cell-culture. From the isolator system, test tubes are taken out. The bone marrow fluid in the test tubes and the concentrate are subjected to a safety test, etc.

Abstract: A solubilized notochordal cell matrix powder dissolved in a carrier solvent or formed as a gel is provided. The notochordal cell matrix powder originates from lyophilized and treated porcine nucleus pulposus tissue containing notochordal cells. The powder contains less than 20% of porcine nucleid acids, and the powder contains a substantially unchanged amount of porcine protein content compared to the originating porcine nucleus pulposus tissue. The solubilized notochordal cell matrix powder is capable of stimulating native or stem cells to proliferate and produce a significant increase in glycosaminoglycans and type-II collagen matrix. Embodiments of the invention can be used as a lubricant with regenerative potential for application in the osteoarthritic joint.

Abstract: An osteoinductive composition is provided which includes a plurality of surface demineralized fibrous bone chips. Each fibrous bone chip has a BET surface area from about 10 m2/gm to about 70 m2/gm. The osteoinductive composition can also include fully demineralized bone fibers. The osteoinductive composition including the surface demineralized fibrous bone chips with or without fully demineralized bone fibers can be placed in a covering, such as a mesh bag. The osteoinductive composition can include other bone structures and/or bioactive agents and/or ceramics. A method of treating a bone cavity in a patient in need thereof with the osteoinductive composition including a plurality of surface demineralized fibrous bone chips with or without fully demineralized bone fibers is also provided.

Abstract: Described herein are compositions and methods related to use of exosomes, including cardiosphere derived cell (CDC)-derived exosomes for treatment and prevention of heart related disease and conditions, such as ventral arrhythmias, such as tachycardias. CDC-derived exosomes delivered by endocardial injection can diminish the total amount of isolated late potentials associated with an isthmus of slow conduction, while reducing the isoelectric interval between late abnormal ventricular activity and decreasing the incidence of inducible ventricular arrhythmias, thereby providing a biological treatment for arrhythmias which otherwise requires therapeutic interventions with adverse effects.

Abstract: The present invention relates to a population of amniocytes having phagocytic activity against pathological cells, such as tumour cells or the cells of other cellular diseases, such as, for example, proliferative vitreoretinopathy, the process for the preparation thereof and uses thereof in the medical field.

Abstract: Provided herein are methods and compositions for a suicide gene approach comprising an expression vector comprising a cell cycle-dependent promoter driving the expression of a suicide gene. Also provided herein are methods to render proliferative cells sensitive to a prodrug after transplantation but avoids expression of the suicide gene in post-mitotic cells, such as neurons.

Abstract: Methods are described herein for identifying and providing prebiotic compositions that are optimized for the health needs of individuals.

Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

Abstract: Disclosed is a composition comprising an effective amount of a mixture of inactivated Escherichia coli and Enterococcus faecalis as well as pharmaceutically acceptable excipients and/or carriers for use in the treatment, supportive treatment or prevention of dermatologic conditions and diseases.

Abstract: A method is disclosed. The method is generally useful for modifying a skin microbiome. The method comprises administering a topical composition to a subject's skin. A topical composition is also disclosed. The topical composition may be used for the method. The topical composition comprises a population of microorganisms, a component obtained from the population of microorganisms, or a combination thereof. The population of microorganisms is generally a Corynebacterium species. The Corynebacterium species comprises at least about 90%, optionally at least about 97%, sequence identity to a 16S rRNA sequence (SEQ ID NO: 1).

Abstract: A probiotic formulation is provided including one or more bacteria, bacterial strains or bacterial species of the genus Veillonella, genus Faecalibacterium, genus Phascolarctobacteria, genus Oscillospira, genus Ruminococcus, genus Bacteroides, genus Blautia, family Christensenellaceae, genus Dialister, or phylum cyanobacteria.

Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.

Abstract: The invention relates to the production of phage and transduction particles using DNAs (eg, plasmids and helper phage, mobile genetic elements (MGEs) or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these.

Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-5 (accession number KCTC 13029BP) isolated from nature characterized by having a capability for specifically killing Vibrio parahaemolyticus bacteria and having a genome expressed by the SEQ ID NO:1, and to a method for preventing and treating infections from Vibrio parahaemolyticus bacteria by means of a composition comprising the Myoviridae bacteriophage Vib-PAP-5 as an active ingredient.

Abstract: The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.

Abstract: Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides an oncolytic virus capable of killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic viruses described herein are suitable for treatment of several types of cancer, including glioblastoma.

Abstract: An extract obtained from Saxifraga sp., Astrantia major, or a combination thereof and a method of treating or relieving an inflammatory-skin related condition in a subject is provided. The method comprises administering or applying a composition comprising an effective amount of an extract from Saxifraga sp., Astrantia major or a combination thereof, and a carrier, wherein the effective amount of the extract inhibits tumor necrosis factor alpha and Interleukine-1beta activity. The inflammation may be inflammation of the skin and the composition may be a skin preparation for external use.

Abstract: Oriental medicinal collagen food and manufacturing method of the oriental medicinal collagen food for skin beauty enhancement are provided. The manufacturing method including: a first process including: removing claws and scales from chicken feet, and preparing dandelion, angelica gigas, and pueraria root; a second process including: performing high-pressure pasteurization for the chicken feet obtained in the first process; a third process including: preparing dandelion extract by heating the dandelion in a bag; a fourth process including: obtaining Gyepogyo by heating and fermenting the pasteurized chicken feet and the dandelion extract in a pot; and a fifth process including: obtaining extract and distillate from a distillation of a mixture comprising the Gyepogyo, the angelica gigas, and the pueraria root.

Abstract: A nutraceutical composition containing (i) garden cress, (ii) nigella saliva, (iii) commiphora myrrha, and (iv) fenugreek for treating male infertility and a method of treating symptomatic reproductive indicators of male infertility such as sperm concentration, sperm count, and progressive sperm motility by administering an effective amount of the nutraceutical composition having an effective proportion of each constituent.

Abstract: The present technology relates generally to pediculicide compositions, method of use, and kits thereof. In particular, disclosed herein is improved pediculicide compositions comprising one or more abrasive materials. The present technology is useful for treating human head lice, Pediculus humanus capitis, through abrasives to break lice and its nits. Preferably, the compositions lack toxic and regulated pediculicide active ingredients, are free of preservatives, and require only a single application to hair.

Abstract: A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.

Abstract: The present invention describes extracts of Polygonum cuspidatum and related compositions that are capable of photodynamic inactivation (PDI) of microorganisms such as bacteria, viruses, fungi, and protozoa, and capable of killing or inactivating cancer cells. The present invention further describes methods of using said Polygonum cuspidatum extracts and photodynamic inactivation (PDI) as a therapy for the treatment of microbial infection and as well as the use of Polygonum cuspidatum extract and related compositions as photodynamic therapy agents for the treatment of cancer.

Abstract: The present application discloses a solid beverage for conditioning allergic constitution. The solid beverage comprises the following components in parts by weight: 18-45 parts of smoked plum, 10-30 parts of perilla, 18-45 parts of lilium brownii, 10-30 parts of purslane, 10-30 parts of coix seed, 10-30 parts of semen hoveniae, 7-20 parts of dahurian angelica, 15-40 parts of dextrin, 9-23 parts of maltodextrin, 9-23 parts of soluble starch and 0.1-0.3 parts of aspartame. The solid beverage of the present application is simple and convenient to prepare, the raw materials used are all medicinal materials with dual-purpose of drug and food, and the auxiliary materials used also meet the national standard GB2760-2011 (the National Food Safety Standard for Food Additive Use). Thus, the solid beverage is safe to consume and good in taste, and has certain effects on the improvement of allergic constitution, and the production process thereof is suitable for industrial mass production.

Abstract: The present invention provides a method for cell rejuvenation, including contacting cells with a composition containing a Rosa roxburghii fruit extract obtained by extraction of a Rosa roxburghii fruit using water, alcohol, or mixtures of water and alcohol as solvents. Said extract improves DNA repair, reduces cell damage caused by oxidative stress or inflammation, maintains the normal functions of genes, proteins, and mitochondria, facilitates telomerase reaction and reduces telomere damage by chemicals or UV radiation, thereby improving cell rejuvenation.

Abstract: The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption.

Abstract: A plant extract obtained from saffron, with a safranal concentration, measured using the HPLC method, of a minimum of 0.2% by weight relative to the total dry matter weight. A method for obtaining the plant extract, as well as compositions comprising the plant extract, and methods of treatment.

Abstract: Disclosed are cosmetic and dermatological formulations which contain all natural ingredients, and particularly plant based ingredients, while excluding water, unnecessary fillers, artificial fragrances and harmful preservatives which might be irritants to the skin. The natural plant based formulations presented herein can be used for treating and/or alleviating skin disorders including dermatitis, eczema, rough skin, cracking and itchy skin. The formulations incorporate a mixture of plant based ingredients including Butyrospermum parkii (shea butter), Cocos nucifera (virgin coconut oil), Vera alba (beeswax), essential oils and d-alpha tocophera (vitamin E).

Abstract: The present disclosure provides a Pennisetum extract, process for manufacturing the same, and uses thereof for inhibiting differentiation and/or activation of osteoclast, and prevention and/or treatment of osteoporosis.

Abstract: A solid beverage for conditioning qi deficiency constitution. The solid beverage includes the following components in parts by weight: 25-60 parts of polygonatum odoratum, 30-52 parts of fuling, 28-53 parts of Chinese dates, 26-48 parts of arillus longan, 15-34 parts of orange peels, 30-53 parts of lilium brownii, 27-52 parts of Chinese yam, 26-56 parts of hyacinth bean, 37-77 parts of dextrin, 15-43 parts of maltodextrin, 18-50 parts of soluble starch and 0.1-0.38 parts of aspartame.

Abstract: A solid drink includes the following components of raw materials in parts by weight: kudzu vine root 25-60 parts, nutmeg 13-35 parts, fructus perillae 30-50 parts, radish seed 34-53 parts, dried tangerine peel 28-55 parts, poria 27-52 parts, fructus amomi 4-15 parts, malt 26-50 parts, agastache rugosa 14-33 parts, kelp 24-51 parts, semen coicis 22-40 parts, dextrin 50-90 parts, maltodextrin 38-70 parts, soluble starch 35-70 parts, and aspartame 0.1-0.5 parts.

Abstract: What is described is a formulation comprising curcuma longa, black pepper containing piperine, ginger, magnesium citrate, and lemon juice extract in an amount for reducing the duration and severity of discomfort caused by gluten ingestion. The formulation reduces gastrointestinal inflammation and gastrointestinal upset, improves gut motility, and/or reduces anxiety and irritability.

Abstract: Provided herein are pharmaceutical compositions for local administration of metabolic inhibitors, methods of locally administering such compositions, and rapid diagnostic methods for identifying mutant allele during the course of a surgical procedure.

Abstract: There is provided a composition for improving memory, learning ability, and cognitive ability and a method of enhancing a brain or cognitive function by administering the composition to a subject in need thereof. It has been confirmed that a peptide having a C-terminal region ended to GAG had an effect of improving the memory. In order for the peptide to have the effect, it has been confirmed that the peptide should be a peptide of which the length consists of at least 4 amino acids. Further, it has been confirmed that a peptide of which the length of the peptide having the C-terminal region ended to GAG consists of 5 to 9 amino acids has the same effect. As a result, the peptide of the present invention can be used as the composition for improving memory, learning ability, and cognitive ability, and the method of enhancing a brain or cognitive function.

Abstract: The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.

Abstract: Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.

Abstract: A composition comprising an antimicrobial polypeptide and at least one antibiotic.

Abstract: Described are novel female fertility therapies. A first aspect of the invention is directed to therapies that include FSH lowering methodologies to prevent and/or treat egg infertility. A second aspect of the invention is directed to agents that bind to activin, bind to receptors that bind activin, or that otherwise disrupt activin signaling (collectively referred to herein as “activin pathway modifier agents” or “APM agents”) and methods of utilizing these agents to prevent and/or treat egg infertility. A third aspect of the invention is directed to methods of administering an effective amount of an APM agent to a subject to increase oocyte yield and/or ovarian reserve. All three aspects of the invention may be used in humans and in animals. Additional aspects of the invention include therapeutic drug kits for treatment of humans and animals based on the methodologies described above.